All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
8 results for "Cancer" and "Gastrointestinal Cancers" and "Leukemia"
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
To evaluate the safety and tolerability of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations and characterize safety and tolerability to determine RP2D of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations.
Protocol No
HMP-2020-306-GLOB1
A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Protocol No
IIT-ABEDIN-LINTUZUMAB-AML
A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients With Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
To determine the recommended Phase 2 dose (RP2D) and tolerability profile of XmAb18968 in subjects with relapsed/refractory acute leukemia and T-LBL with CD38 expression
Protocol No
IIT-ATALLAH-MCW-XEN21
A Phase 1 Study of JNJ-75276617 in Participants with Acute Leukemia
This project is being done to see if a safe dose of JNJ-75276617 can be identified for treating participants with acute leukemia, including acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Protocol No
JNJ-75276617ALE1001
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies
To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of oral LOXO-338 in patients with previously treated advanced hematologic malignancies.
Protocol No
LOXO-BCL-20001
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Protocol No
GENMAB-GCT3014-01
A Multi-Center, Open Label Phase 1/2 Study of Cyt-0851, an Oral Rad51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin s Lymphoma (NHL)
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Protocol No
LOXO-BTK-18001